Prosthetic vascular graft infection is a rare but very severe complication coursing with high morbi-mortality rates. Its treatment requires appropriate surgical procedures combined with adequate antimicrobial treatment in reference centers. The authors report the clinical case of a 71 years old patient, diagnosed with early prosthetic graft infection 3 months after implantation of a femoro-femoral crossover and a prosthetic- popliteal bypass, treated conservatively, with extensive surgical debridement, preservation of the graft and empirical bactericidal broad spectrum antibiotherapy. The clinical case offers the opportunity to review and discuss the diagnosis and therapeutic issues in prosthetic vascular graft infections. Research is needed to allow an estimation of the risks and benefits of the different therapeutic approaches.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Maintenance Immunosuppression With Tacrolimus and Everolimus in Heart Transplantation Compared With the Usual Tacrolimus and Micophenolate Protocol: Results From a Retrospective Registry.
Transplant Proc
January 2025
Department of Cardiology, Advanced Heart Failure and Heart Transplant Unit, Hospital Universitario Central de Asturias, Oviedo, Spain; Health Research Institute of Asturias, ISPA, Oviedo, Spain.
Introduction: Real-life data on the long-term use of a maintenance immunosuppressive protocol in heart transplant patients using delayed Everolimus + Tacrolimus are scarce.
Methods: This is a retrospective study that included all heart transplant patients from 2011 to 2021 in two Spanish hospitals. In Hospital A, the preferred immunosuppressive strategy included Everolimus initiation at 2 months post-transplant combined with Tacrolimus and was compared with the results of Hospital B, where a standard Tacrolimus and Mycophenolate mofetil protocol was used.
Mucormycosis Infection in Lung Transplant Patients: Experience in Andalusia, Spain.
Transplant Proc
January 2025
Department of Thoracic Surgery and Lung Transplantation, University Hospital Reina Sofía, Córdoba, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba, IMIBIC, University of Córdoba, Córdoba, Spain; Group for the Study of Thoracic Neoplasms and Lung Transplantation, IMIBIC (Instituto Maimónides de Investigación Biomédica de Córdoba), University of Córdoba, Córdoba, Spain. Electronic address:
Introduction: Mucorales infections in the airways of lung transplant (LT) patients are rare but have a rising incidence in transplanted lungs.
Objective: We present our experience with LT in immediate postoperative infections due to mucormycosis.
Methods: Review of 767 LT performed in Andalusia between 2000 and 2023 identifying Mucorales through microbiological results and histological findings.
Hemophagocytic Lymphohistiocytosis in a Kidney Transplant Recipient: Case Report.
Transplant Proc
January 2025
Nephrology, Hospital Universitario Donostia, San Sebastián, España.
Hemophagocytic lymphohistiocytosis is a potentially fatal multisystemic inflammatory syndrome that is better understood in the pediatric population. Consequently, the diagnostic criteria for adults still derives from studies conducted in the pediatric population. Several genetic mutations and secondary causes, including infections, autoimmunity, and malignancy, have been reported as significant actors in this condition, especially in adults.
View Article and Find Full Text PDFMIF/CD74 axis in hepatic stellate cells mediates HBV-related liver fibrosis.
Int Immunopharmacol
January 2025
Department of Transplantation Immunology, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, Jilin Province 130061, China. Electronic address:
Chronic hepatitis B virus (HBV) infection is a major risk factor for liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Despite advances in understanding HBV-related liver diseases, effective therapeutic strategies remain limited. Macrophage migration inhibitory factor (MIF) has been implicated in various inflammatory and fibrotic conditions, but its role in HBV-induced liver fibrosis has not been fully explored.
View Article and Find Full Text PDFContext-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer.
Nat Cancer
January 2025
Cancer Systems Biology Laboratory, The Francis Crick Institute, London, UK.
CDKN2A is a tumor suppressor located in chromosome 9p21 and frequently lost in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). How CDKN2A and other 9p21 gene co-deletions affect EAC evolution remains understudied. We explored the effects of 9p21 loss in EACs and cancer progressor and non-progressor BEs with matched genomic, transcriptomic and clinical data.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!